Premium
Antiplatelet therapy after endovascular intervention: Does combination therapy really work and what is the optimum duration of therapy?
Author(s) -
Milani Richard V.
Publication year - 2009
Publication title -
catheterization and cardiovascular interventions
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.988
H-Index - 116
eISSN - 1522-726X
pISSN - 1522-1946
DOI - 10.1002/ccd.21996
Subject(s) - medicine , clopidogrel , aspirin , antithrombotic , ticlopidine , myocardial infarction , peripheral , arterial disease , combination therapy , cardiology , stroke (engine) , platelet aggregation inhibitor , surgery , vascular disease , engineering , mechanical engineering
The number of patients undergoing peripheral interventions has increased in recent years, highlighting the need for a safe and effective protective antithrombotic therapy. Platelet inhibition following coronary intervention is associated with a significantly reduced risk of graft occlusion, and has been acknowledged to be safe and effective in patients with peripheral arterial disease. Monotherapy with either aspirin or clopidogrel, reduces the rate of stroke, myocardial infarction, and cardiovascular death in patients suffering from peripheral arterial disease. Limited data from clinical trials investigating combination therapy of aspirin with ticlopidine or clopidogrel in patients undergoing endovascular interventions, have suggested the potential for a reduction in cardiovascular events. Nevertheless, the optimal duration of postintervention antiplatelet therapy remains to be defined. © 2009 Wiley‐Liss, Inc.